Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

RMD Open
P J MeaseLuminita Pricop

Abstract

To assess the long-term (3 year) efficacy and safety of secukinumab in patients with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study (NCT01892436). Following the 2-year core trial, eligible patients receiving subcutaneous secukinumab 150 or 75 mg entered a 3-year extension phase. Results are presented for key efficacy and safety endpoints at week 156. In total, 460 patients entered the extension study; 308 patients originally randomised to secukinumab were assessed for efficacy. Sustained improvements in all efficacy endpoints were achieved with secukinumab through week 156. Overall, 76.8%/54.9% (secukinumab 150 mg) and 65.2%/39.0% (secukinumab 75 mg) of patients achieved an American College of Rheumatology (ACR) 20/50 response (multiple imputation data); ACR20 responses were sustained irrespective of previous anti-tumour necrosis factor exposure. Improvements in quality of life and physical function were also sustained through week 156. Radiographic results (observed data; van der Heijde modified total Sharp score (mTSS)) showed that 78.1% (secukinumab 150 mg) and 74.8% (secukinumab 75 mg) of patients had no radiographic progression (≤0.5 increase in mTSS) through week 156. Exposure-adjusted incid...Continue Reading

References

May 18, 1999·Journal of Epidemiology and Community Health·C JenkinsonC Paice
Feb 15, 2005·Annals of the Rheumatic Diseases·D D GladmanP Nash
Feb 15, 2005·Annals of the Rheumatic Diseases·D van der HeijdeD D Gladman
Jul 28, 2006·Arthritis and Rheumatism·William TaylorUNKNOWN CASPAR Study Group
Feb 9, 2007·The New England Journal of Medicine·Gerald G KruegerUNKNOWN CNTO 1275 Psoriasis Study Group
Oct 28, 2008·Annals of the Rheumatic Diseases·C T RitchlinUNKNOWN Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
Aug 28, 2009·The New England Journal of Medicine·Pierre MiossecVijay K Kuchroo
Oct 12, 2010·Science Translational Medicine·Wolfgang HueberFranco Di Padova
Jan 11, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Bernadette PöllingerAmanda Littlewood-Evans
Sep 29, 2011·Annals of the Rheumatic Diseases·L GossecUNKNOWN European League Against Rheumatism
Oct 21, 2011·The Journal of Investigative Dermatology·Kenneth B GordonJoaquin M Valdes
Apr 26, 2012·Annals of the Rheumatic Diseases·Anna JamnitskiMichael T Nurmohamed
Dec 12, 2012·Therapeutic Advances in Musculoskeletal Disease·Irene E van der Horst-Bruinsma, Michael T Nurmohamed
Mar 16, 2013·Current Opinion in Rheumatology·Philip Mease
Apr 9, 2013·Annals of the Rheumatic Diseases·Karen Minde FagerliTore K Kvien
Jun 19, 2013·American Journal of Clinical Dermatology·Wolf-Henning Boehncke, Alan Menter
Jul 28, 2013·Rheumatology·Laura C CoatesUNKNOWN BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR
Jul 10, 2014·The New England Journal of Medicine·Richard G LangleyUNKNOWN FIXTURE Study Group
Oct 1, 2015·The New England Journal of Medicine·Philip J MeaseUNKNOWN FUTURE 1 Study Group
Dec 25, 2015·The New England Journal of Medicine·Dominique BaetenUNKNOWN MEASURE 2 Study Group
Mar 30, 2018·Frontiers in Medicine·Anna Moltó, Elena Nikiphorou

❮ Previous
Next ❯

Citations

Mar 23, 2019·The Journal of Dermatological Treatment·Kevin K WuJashin J Wu
Apr 3, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·M AugustinR Orsenigo
Nov 14, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·N D LoftA Egeberg
Jul 15, 2020·Nature Reviews. Rheumatology·Eric GraceyDirk Elewaut
Jul 7, 2019·Annals of the Rheumatic Diseases·Dennis G McGonagleRobert Moots
Apr 29, 2020·Annual Review of Immunology·Nico GhilardiAndrew C Chan
Jan 25, 2021·Autoimmunity Reviews·Solveig Skovlund GroenSigne Holm Nielsen
Feb 18, 2021·RMD Open·Roberta RamondaUNKNOWN on behalf Spondyloartritis and Psoriatic Arthritis SIR Study Group “Antonio Spadaro”
Nov 17, 2020·Frontiers in Medicine·Angelo FassioLuca Idolazzi
Nov 19, 2020·Immunotherapy·Scott H BergSteven R Feldman
Mar 5, 2021·Drugs·Hannah A Blair
Apr 17, 2021·American Journal of Clinical Dermatology·Akshitha ThatiparthiJashin J Wu
Jul 10, 2021·International Journal of Rheumatic Diseases·Jinxian HuangJames C-C Wei
Jul 27, 2021·Expert Opinion on Drug Safety·Bénédicte CaronLaurent Peyrin-Biroulet
Feb 6, 2020·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Alice B GottliebLuminita Pricop
Oct 31, 2019·Case Reports in Dermatology·Anna CampanatiAnnamaria Offidani

❮ Previous
Next ❯

Methods Mentioned

BETA
MDA
X-ray

Clinical Trials Mentioned

NCT01892436

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.